ESTRO 2024 - Abstract Book

S761

Clinical - CNS

ESTRO 2024

Conclusion:

This interim report of a proof-of-concept study presents baseline 18F-fluciclovine metrics for patients with brain metastases, encompassing a range of lesion sizes and volumes. All baseline lesions >5 mm were associated with increased uptake, providing baseline estimates. Interim results demonstrate that following SSRS treatment, target lesions (as well as bystander lesions treated with SRS) exhibit a greater objective reduction in PET metrics than MRI dimensional and/or volumetric measurements, supporting the hypothesis that 18F-fluciclovine PET/CT may serve as a more sensitive biomarker of treatment response.